C Holm1,2, L L Thomsen2, A Norgaard3, J Langhoff-Roos1. 1. Department of Obstetrics, Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 2. Pharmacosmos A/S, Holbaek, Denmark. 3. Section for Transfusion Medicine, Capital Region Blood Bank, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND AND OBJECTIVES: To evaluate the clinical efficacy of a single-dose intravenous infusion of iron isomaltoside compared with current treatment practice with oral iron measured by physical fatigue in women after postpartum haemorrhage. MATERIALS AND METHODS: Single-centre, open-label, randomized controlled trial. Participants received intravenous iron (n = 97) or oral iron (n = 99), and completed the Multidimensional Fatigue Inventory and Edinburgh Postnatal Depression Scale, and haematological and iron parameters were measured. Primary outcome was the aggregated change in physical fatigue score from baseline to 12 weeks postpartum. RESULTS: The difference in physical fatigue score was -0·97 (95% CI: -1·65; -0·28, P = 0·006) in favour of intravenous iron, but did not meet the predefined difference of 1·8. Across visits, we found statistically significant differences in fatigue and depression scores, as well as in haematological and iron parameters, all in favour of intravenous iron. There were no serious adverse reactions. CONCLUSION: A single dose of intravenous iron was associated with a statistically significant reduction in aggregated physical fatigue within 12 weeks after postpartum haemorrhage compared to standard medical care with oral iron below the prespecified criteria of clinical superiority. As patient-reported outcomes improved significantly and intravenous iron resulted in a fast hematopoietic response without serious adverse reactions, intravenous iron may be a useful alternative after postpartum haemorrhage if oral iron is not absorbed or tolerated.
RCT Entities:
BACKGROUND AND OBJECTIVES: To evaluate the clinical efficacy of a single-dose intravenous infusion of iron isomaltoside compared with current treatment practice with oral iron measured by physical fatigue in women after postpartum haemorrhage. MATERIALS AND METHODS: Single-centre, open-label, randomized controlled trial. Participants received intravenous iron (n = 97) or oral iron (n = 99), and completed the Multidimensional Fatigue Inventory and Edinburgh Postnatal Depression Scale, and haematological and iron parameters were measured. Primary outcome was the aggregated change in physical fatigue score from baseline to 12 weeks postpartum. RESULTS: The difference in physical fatigue score was -0·97 (95% CI: -1·65; -0·28, P = 0·006) in favour of intravenous iron, but did not meet the predefined difference of 1·8. Across visits, we found statistically significant differences in fatigue and depression scores, as well as in haematological and iron parameters, all in favour of intravenous iron. There were no serious adverse reactions. CONCLUSION: A single dose of intravenous iron was associated with a statistically significant reduction in aggregated physical fatigue within 12 weeks after postpartum haemorrhage compared to standard medical care with oral iron below the prespecified criteria of clinical superiority. As patient-reported outcomes improved significantly and intravenous iron resulted in a fast hematopoietic response without serious adverse reactions, intravenous iron may be a useful alternative after postpartum haemorrhage if oral iron is not absorbed or tolerated.
Authors: Pervez Sultan; Sohail Bampoe; Raj Shah; Nan Guo; Jaclyn Estes; Christopher Stave; Lawrence Tim Goodnough; Stephen Halpern; Alex James Butwick Journal: Am J Obstet Gynecol Date: 2018-12-19 Impact factor: 8.661
Authors: Dante A Suffredini; Wanying Xu; Junfeng Sun; Jesús Barea-Mendoza; Steven B Solomon; Samuel L Brashears; Andreas Perlegas; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson; Irene Cortés-Puch Journal: Transfusion Date: 2017-06-27 Impact factor: 3.157
Authors: Michael Auerbach; David Henry; Richard J Derman; Maureen M Achebe; Lars L Thomsen; John Glaspy Journal: Am J Hematol Date: 2019-07-13 Impact factor: 10.047
Authors: Richard Derman; Eloy Roman; Gioi N Smith-Nguyen; Maureen M Achebe; Lars L Thomsen; Michael Auerbach Journal: Am J Hematol Date: 2018-06 Impact factor: 10.047
Authors: Sunil Bhandari; Philip A Kalra; Mario Berkowitz; Diogo Belo; Lars L Thomsen; Myles Wolf Journal: Nephrol Dial Transplant Date: 2021-01-01 Impact factor: 5.992